Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.
Nedavne studije su međutim pokazale da tezosentan ne poboljšava dispneju niti redukuje rizik od kardiovakularnih problema.